Compare Fortinet Inc (FTNT) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs GSK plc — how do they compare? Fortinet Inc trades at $163.28 (market cap $120.53B), while GSK plc trades at $52.34 (market cap $101.34B). The key difference: Fortinet Inc is the larger of the two by market cap, and GSK plc pays a 3.49% dividend while Fortinet Inc pays none. Which is the better fit depends on your goals.
| FTNT | GSK | |
|---|---|---|
Market Cap | $120.53B | $101.34B |
Sector | Technology | Health |
52-Week High | $166.83 | $61.18 |
52-Week Low | $74.39 | $36.20 |
Enterprise Value | $117.73B | $121.95B |
Dividend Yield | — | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $166.83, up 3.87% today, with a bullish technical signal from moving averages and strong quarterly earnings beats. Revenue grew to $6.80B in 2025, with a net income margin of 27.49%, though valuation ratios like P/E of 63.76 and P/S of 17.5 appear elevated. Recent news highlights AI-driven cybersecurity demand as a growth catalyst, with the company expanding its FortiEndpoint platform for AI security.
The outlook is positive due to robust earnings performance and sector tailwinds, but high valuations and competitive pressures pose risks. Analyst consensus is mixed with 42.65% buy ratings, yet the consensus price target of $123.16 suggests caution relative to the current price, indicating potential overvaluation concerns amid growth optimism.
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
